Clinical trials: Neoplasia GI
Advanced or Metastatic Solid Tumors
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
To evaluate the efficacy of naporafenib administered with trametinib in patients with rat sarcoma viral oncogene (RAS) Q61X solid tumors To evaluate the safety and tolerability of naporafenib administered with trametinib in…
- Trial name
- SEACRAFT-1 (NCT05907304)
- Testing
- Naporafenib, Trametinib
- Where
- 29 sites in United States, Australia and 3 more
- Volunteers
- 86 people
- Sponsor
- Erasca, Inc.
Colorectal Neoplasm, Digestive System Neoplasm
Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors.
This study will include two parts: In the phase I part: safety will be assessed in consecutive cohorts of 3 to 6 patients at increasing doses of TG6002 in combination with oral flucytosine (5-FC) in patients with advanced…
- Trial name
- NCT03724071
- Testing
- TG6002, Flucytosine (5-FC, Ancotil)
- Where
- 7 sites in Belgium, France and 1 more
- Volunteers
- 51 people
- Sponsor
- Transgene
Gastric Cancer, Esophageal Cancer
a Single-arm, Single-center, Open Clinical Study
This trial plans to enroll many patients with advanced solid tumors to complete GK01 cell transfusion, including but not limited to advanced gastric cancer, esophageal cancer, cervical cancer, triple-negative breast cancer, and…
- Conditions
- Gastric Cancer, Esophageal Cancer, Cervical Cancer, Non-Small Cell Lung Cancer NSCLC
- Trial name
- GK-01 (NCT06431100)
- Testing
- TCR T-cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Beijing Geekgene Technology Co., LTD
Refractory Metastatic Colorectal Cancer, pMMR
RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
This is an open-label, Phase 2 clinical trial evaluating therapy with an oncolytic immunotherapy (RP2 or RP3) in combination with atezolizumab and bevacizumab in patients with advanced Microsatellite Stable and Mismatch Repair…
- Conditions
- Refractory Metastatic Colorectal Cancer, pMMR, MSS
- Trial name
- NCT05733611
- Testing
- RP2, RP3, atezolizumab
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Replimune, Inc.
CRC
Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC)
The study consists of the two parts, phase IIa and phase IIb.
- Trial name
- mCRC (NCT05233332)
- Testing
- HL-085, Vemurafenib
- Where
- China
- Volunteers
- 186 people
- Sponsor
- Shanghai Kechow Pharma, Inc.
Neoplasms
A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent
N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin.
- Trial name
- NCT00264433
- Testing
- ADH -1 (Exherin™)
- Where
- 11 sites in United States, Canada
- Sponsor
- Adherex Technologies, Inc.
Colorectal Polyp
Computer Aided Detection of Polyps in Colonoscopy
The aim of this study is to evaluate the clinical benefit and safety of using a computer aided detection device, Skout, for real-time polyp detection in colonoscopy procedures with the indication of screening or surveillance.
- Trial name
- NCT04754347
- Testing
- Computer Aided Detection device
- Where
- 5 sites in United States
- Volunteers
- 1,472 people
- Sponsor
- Iterative Scopes, Inc
Colorectal Cancer
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer.
This single arm study will assess the efficacy and safety of a combination of modified FOLFIRI (irinotecan, 5-FU and leucovirin), Avastin and cetuximab in patients with previously untreated metastatic colorectal cancer.
- Trial name
- NCT00577109
- Testing
- bevacizumab [Avastin], Irinotecan, Leucovorin
- Where
- 3 sites in Brazil
- Sponsor
- Hoffmann-La Roche
Gastric Cancer
A Study of LY2875358 in Participants With MET Positive, Advanced Gastric Cancer
The main purpose of this study is to evaluate the effectiveness of LY2875358 in participants with MET diagnostic positive (+), advanced gastric or gastroesophageal junction (GEJ) cancer.
- Trial name
- NCT01874938
- Testing
- LY2875358
- Where
- 3 sites in Japan, South Korea
- Volunteers
- 15 people
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumors, Triple Negative Breast Cancer
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
The purpose of this study is to determine the safety and efficacy of combination therapy with pembrolizumab (MK-3475) and lenvatinib (E7080/MK-7902) in participants with triple negative breast cancer (TNBC), ovarian cancer…
- Conditions
- Advanced Solid Tumors, Triple Negative Breast Cancer, Ovarian Cancer, Gastric Cancer
- Trial name
- NCT03797326
- Testing
- Pembrolizumab, Lenvatinib
- Where
- 88 sites in United States, Argentina and 15 more
- Volunteers
- 611 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Cancer, Advanced Adenocarcinoma
A Multicenter Clinical Trial of Stool-based DNA Testing for Early Detection of Colon Cancer in China
According to data from Global Cancer Statistics 2018, colorectal cancer (CRC) ranks second in incidence and fifth in mortality among all cancers in China.
- Conditions
- Colorectal Cancer, Advanced Adenocarcinoma, Hyperplastic Polyp, Colorectal Neoplasms
- Trial name
- NCT04722055
- Testing
- Multigene Methylation Detection Kit
- Where
- China
- Volunteers
- 1,273 people, healthy volunteers welcome
- Sponsor
- Creative Biosciences (Guangzhou) Co., Ltd.
Advanced Gastrointestinal Stromal Tumor
Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal Tumors
The purpose of the study is to evaluate the safety and efficacy of AMG 706 in patients with gastrointestinal stromal tumor that have not been controlled while taking imatinib mesylate.
- Trial name
- NCT00254267
- Testing
- AMG 706
- Volunteers
- 35 people
- Sponsor
- Amgen
Advanced Solid Tumors
Phase I Study of OSI-930 and Erlotinib in Cancer Tumors
This is a Phase I, dose escalation, safety study of OSI-930 and Erlotinib in cancer tumors.
- Trial name
- NCT00603356
- Testing
- OSI-930 and erlotinib
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 60 people
- Sponsor
- Astellas Pharma Inc
Cachexia; Cancer, Cachexia
Master Protocol for the Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC
The purpose of this trial is to learn whether participants who take rilogrotug gain weight, have a better appetite, and have a better quality of life than participants who do not take rilogrotug (placebo arm).
- Conditions
- Cachexia; Cancer, Cachexia, Cachexia-Anorexia Syndrome, Metastatic Colorectal Cancer (CRC)
- Trial name
- REACH (NCT07888075)
- Testing
- Rilogrotug
- Volunteers
- 950 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Metastatic Breast Cancer, Metastatic Gastric Cancer
Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With Herceptin® in Healthy Male Volunteers
Trastuzumab for injection is a biosimilar of Herceptin ® produced by Chia Tai Tianqing Biotechnology Co., LTD, which is a humanized IgG1 monoclonal antibody produced by chinese hamster ovary (CHO) cells.
- Trial name
- NCT05765357
- Testing
- Trastuzumab for injection, Herceptin
- Where
- China
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Breast Cancer, Pancreas Cancer
Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
Phase 1 A: First-in-human phase 1 study to determine safety of NP-G2-044 when given orally on a daily X 28 days followed by a 14 day rest period.
- Conditions
- Breast Cancer, Pancreas Cancer, Prostate Cancer, Lung Cancer
- Trial name
- NCT03199586
- Testing
- NP-G2-044
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Novita Pharmaceuticals, Inc.
Colorectal Cancer
Pharmacodynamic Evaluation of Stool Output Following Oral Administration of Various Low Volume PEG3350-based Gut Cleansing Solutions Using the Split Dose Intake in Healthy Subjects
This study is to investigate the effect of various modified low volume polyethylene glycol (PEG) 3350 and ascorbic acid/ascorbate (PEG+ASC)-based gut cleansing solutions on stool output in healthy subjects.
- Trial name
- OUT (NCT01834742)
- Testing
- NER1006, Moviprep
- Where
- 2 sites in Romania
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- Norgine
Breast Cancer, Gastric Cancer
A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors
This clinical trial will enroll subjects with HER2+ solid tumors and is conducted in two phases. The primary objective of Phase 1 is to determine the safety and tolerability of AB-201 in subjects with advanced HER2+ solid tumors.
- Conditions
- Breast Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT05678205
- Testing
- AB-201, Cyclophosphamide, Fludarabine
- Where
- 2 sites in United States, South Korea
- Sponsor
- Artiva Biotherapeutics, Inc.
Rectal Cancer
Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating CEA Positive Rectal Cancer
Conducting an early phase clinical trial to assess CEA Antigen Presentation Therapeutic Biological Product Mix activity that suggests the potential for clinical benefit of CEA positive rectal cancer patients. 1.
- Trial name
- CEA+RC-BCG (NCT02403505)
- Testing
- CEA protein antigen plus BCG Vaccine Mix for percutaneous use
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Gastric Cancer
A Study of Bevacizumab (Avastin) Versus Placebo in Combination With Capecitabine (Xeloda) and Cisplatin as First-Line Therapy for Advanced Gastric Cancer
This 2 arm study will compare the efficacy and safety of bevacizumab in combination with capecitabine and cisplatin versus placebo in combination with capecitabine and cisplatin in participants who have not received prior…
- Trial name
- AVATAR (NCT00887822)
- Testing
- Bevacizumab, Capecitabine, Cisplatin
- Where
- 14 sites in China
- Volunteers
- 202 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.